Volume 1.22 | Aug 13

Human Immunology News 1.22 August 13, 2013
Human Immunology News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Human Immunology News on Twitter
Scientists Identify Biomarker to Predict Immune Response Risk after Stem Cell Transplants
Researchers identified and validated a biomarker accessible in blood tests that could be used to predict which stem cell transplant patients are at highest risk for a potentially fatal immune response called graft-versus-host disease. [Press release from EurekAlert! discussing online prepublication in New England Journal of Medicine] Press Release | Abstract
A New System for High-Throughput Cell Isolation Directly from Whole Blood
PUBLICATIONS (Ranked by impact factor of the journal)
Decreased Gut Microbiota Diversity, Delayed Bacteroidetes Colonization and Reduced Th1 Responses in Infants Delivered by Caesarean Section
Scientists addressed how microbiota development in infants is affected by mode of delivery, and relate differences in colonization patterns to the maturation of a balanced Th1/Th2 immune response. [Gut]
| Press Release

Human Regulatory T Cells against Minor Histocompatibility Antigens: Ex Vivo Expansion for Prevention of Graft-versus-Host Disease
Scientists sought to identify and expand regulatory CD4 T cells (Treg) specific for human minor histocompatibility antigens in numbers and potency adequate for clinical testing. Purified Treg from normal donors were stimulated by dendritic cells from their HLA-matched siblings in the presence of IL-2, IL-15 and rapamycin. [Blood] Abstract

Immune Competence after Alemtuzumab Treatment of Multiple Sclerosis
Investigators aimed to determine the immunocompetency of patients with multiple sclerosis treated with the lymphodepleting humanized monoclonal antibody alemtuzumab. [Neurology] Abstract

A Phase IB Study on Intravenous Synthetic mRNA Electroporated Dendritic Cell Immunotherapy in Pretreated Advanced Melanoma Patients
In this phase IB clinical trial, 24 million viable dendritic cells were administered by four biweekly combined intradermal and intravenous (iv) administrations, and a fifth administration on week 16. Immune responses were assessed by analysis of antigen specificity of blood-derived T-cells and skin infiltrating lymphocytes. [Ann Oncol] Abstract

Autoimmunity against INS-IGF2 Expressed in Human Pancreatic Islets
The authors aimed to determine expression of INS-IGF2 in human pancreatic islets and autoantibodies in newly diagnosed type 1 diabetes children and controls. INS-IGF2, expressed primarily in beta cells, showed higher levels of expression in islets from normal compared to donors with either type 2 diabetes or high HbA1c levels. [J Biol Chem] Abstract | Full Article

CD14+CD33+ Myeloid Cell-CCL11-Eosinophil Signature in Ulcerative Colitis
Scientists tested the hypothesis that eotaxins (CCL11, CCL24, and CCL26) and IL-5 contribute to eosinophil recruitment to the intestine in ulcerative colitis and that intestinal macrophages are important producers of CCL11 in this disease. [J Leukoc Biol] Abstract

CTLA4-Ig (Abatacept) Therapy Modulates T Cell Effector Functions in Autoantibody-Positive Rheumatoid Arthritis Patients
Researchers performed a mechanism of action study to dissect T cell functionality in rheumatoid arthritis patients with long-standing disease undergoing abatacept treatment and the influence of anti-citrullinated protein antibodies status. [BMC Immunol] Full Article

Regulatory T Cells in Behçet’s Disease: Is there a Correlation with Disease Activity? Does Regulatory T Cell Type Matter?
The authors investigated the percentage of regulatory T cells and the correlation with clinical activity in Behçet’s disease (BD). Forty BD patients, 18 males and 22 females, were included in the study. [Rheumatol Int] Abstract

Subscribe to our sister publications: Immunology of Infectious Disease News and Immune Regulation News!

Free Nature Reviews Immunology Poster: The Immune Response to HIV
Perspectives of the Relationship between IL-7 and Autoimmune Diseases
Targeting components in interleukin (IL)-7 signaling pathways may have potential significance for treating numerous autoimmune diseases. The authors summarize their current understandings regarding the relationship between IL-7 and autoimmune diseases so as to render more valuable information on this kind of research. [Clin Rheumatol] Abstract

Visit our reviews page to see a complete list of reviews in the human immunology research field.
Vical Phase III Trial of Allovectin® Fails to Meet Efficacy Endpoints
Vical Incorporated announced top-line results from a Phase III trial of Allovectin® (velimogene aliplasmid), an investigational intratumoral cancer immunotherapy, in patients with metastatic melanoma. The 390-subject trial failed to demonstrate a statistically significant improvement vs. first-line chemotherapy for either the primary endpoint of objective response rate at 24 weeks or more after randomization or the secondary endpoint of overall survival. [Vical Inc.] Press Release

Kite Pharma Appoints Leading Cancer Immunotherapy Experts to its Scientific Advisory Board
Kite Pharma Inc. announced the appointment of three leading experts in the areas of immunotherapy, chimeric antigen receptor technology, and gene therapy to its Scientific Advisory Board. [PR Newswire Association LLC] Press Release

Regulatory Update – GSK Announces EU Submission for Cervarix® Two Dose Schedule
GlaxoSmithKline (GSK) plc announced the submission of a regulatory application in the European Union (EU) for a two dosing schedule in 9-14 year old girls for its cervical cancer vaccine, Cervarix® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant]. [GlaxoSmithKline plc] Press Release

Attend World Vaccine Congress 2013 in Lille, France
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.
NEW 11th World Congress on Inflammation: ImmunoNatal2013
September 21-25, 2013
Natal, Brazil

Visit our events page to see a complete list of events in the human immunology community.
NEW Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

NEW Postdoctoral Research Scientist – Asthma Research (Columbia University – Allergy Immunology Medicine)

Tenure-Track Position – Cell Biologist (McGill University)

Postdoctoral Position – Molecular Immunology (Baylor Institute for Immunology Research)

Postdoctoral Fellow – Role of the IL-23/IL-17 Axis in Inflammatory Arthritis (UC Davis Medical Center)

Postdoctoral Research Scientist – Allergy Immunology Medicine (Columbia University)

Postdoctoral and Senior Research Scientist Positions – Immunology ERC Advanced Grant Project (Technische Universitat Munchen)

PhD Research Position – Immune Tolerance and Autoimmunity (Weizmann Institute of Science)

Research Scientist/Senior Research Officer – Monoclonal Antibodies (Bioprocessing Technology Institute/A*STAR)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Human Immunology News?
Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Human Immunology News: Archives | Events | Contact Us